Clinical trials
Carcinoma, Non-Small-Cell Lung trials in France with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 31 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GERCOR - Multidisciplinary Oncology Cooperative Group | 4 |
| Centre Henri Becquerel | 2 |
| Gustave Roussy, Cancer Campus, Grand Paris | 2 |
| Hospices Civils de Lyon | 2 |
| Adlai Nortye Biopharma Co., Ltd. | 1 |
| Assistance Publique Hopitaux De Marseille | 1 |
| Blueprint Medicines Corporation | 1 |
| Central Hospital, Nancy, France | 1 |
| Centre Georges Francois Leclerc | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 31 |
| Lung Neoplasms | 12 |
| Neoplasm Metastasis | 4 |
| Adenocarcinoma of Lung | 3 |
| Carcinoma, Renal Cell | 3 |
| Head and Neck Neoplasms | 3 |
| Neoplasms | 3 |
| Colorectal Neoplasms | 2 |
| Melanoma | 2 |
| Triple Negative Breast Neoplasms | 2 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.